HanAll Biopharma Co Ltd (009420):企業の財務・戦略的SWOT分析

◆英語タイトル:HanAll Biopharma Co Ltd (009420) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH81901FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:韓国
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥76,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥115,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
HanAll Biopharma Co Ltd (HanAll), formerly HanAll Pharmaceutical Co Ltd, is a developer of generic and specialty drugs for treatment of diseases related to digestive, endocrine, musculoskeletal and urinary system. The company’s pipeline products include HL036, a drug being developed for treating dry eye diseases; HL189 against non-infectious uveitis; IM156 targeting cancers; and HL190 to treat wet age-related macular degeneration. It also sells drugs for treating digestive dysfunction, osteoporosis, liver dysfunction, hepatic coma, metabolic disorders caused due to hypocalcemia, tetania, bone pain and bone lesions. HanAll also conducts research for developing drugs in the therapeutic areas of autoimmune, eye diseases and immuno oncology indications. The company works in partnership with global pharmaceutical companies and academic institutions for advancing its pipeline products. It has operations in South Korea and the US. HanAll is headquartered in Seoul, South Korea

HanAll Biopharma Co Ltd Key Recent Developments

Jan 19,2021: Hanall Biopharma, net profit in 2020 increased by 14% from the previous year to KRW 21.9 billion
Oct 29,2020: Hanall Biopharma achieved sales of 22.1 billion won, operating profit of 1 billion, and net profit of 3.7 billion in the third quarter
Jul 29,2020: Hanol Biopharma achieved 22.6 billion won in sales in 2Q and 1.6 billion in operating profit

This comprehensive SWOT profile of HanAll Biopharma Co Ltd provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of HanAll Biopharma Co Ltd including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

HanAll Biopharma Co Ltd – Key Information
HanAll Biopharma Co Ltd – Overview
HanAll Biopharma Co Ltd – Key Employees
HanAll Biopharma Co Ltd – Key Employee Biographies
HanAll Biopharma Co Ltd – Key Operational Heads
HanAll Biopharma Co Ltd – Major Products and Services
HanAll Biopharma Co Ltd – History
HanAll Biopharma Co Ltd – Company Statement
HanAll Biopharma Co Ltd – Locations And Subsidiaries
HanAll Biopharma Co Ltd
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

HanAll Biopharma Co Ltd – Business Description
HanAll Biopharma Co Ltd – Corporate Strategy
HanAll Biopharma Co Ltd – SWOT Analysis
SWOT Analysis – Overview
HanAll Biopharma Co Ltd – Strengths
HanAll Biopharma Co Ltd – Weaknesses
HanAll Biopharma Co Ltd – Opportunities
HanAll Biopharma Co Ltd – Threats
HanAll Biopharma Co Ltd – Key Competitors

Section 3 – Company Financial Performance Charts

HanAll Biopharma Co Ltd – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

HanAll Biopharma Co Ltd, Key Information
HanAll Biopharma Co Ltd, Key Ratios
HanAll Biopharma Co Ltd, Share Data
HanAll Biopharma Co Ltd, Major Products and Services
HanAll Biopharma Co Ltd, History
HanAll Biopharma Co Ltd, Key Employees
HanAll Biopharma Co Ltd, Key Employee Biographies
HanAll Biopharma Co Ltd, Key Operational Heads
HanAll Biopharma Co Ltd, Other Locations
HanAll Biopharma Co Ltd, Subsidiaries
HanAll Biopharma Co Ltd, Key Competitors
HanAll Biopharma Co Ltd, SWOT Analysis
HanAll Biopharma Co Ltd, Ratios based on current share price
HanAll Biopharma Co Ltd, Annual Ratios
HanAll Biopharma Co Ltd, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[HanAll Biopharma Co Ltd (009420):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Wien Energie GmbH:企業の戦略的SWOT分析
    Wien Energie GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Piksel, Inc.:企業のM&A・事業提携・投資動向
    Piksel, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Piksel, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Intas Pharmaceuticals Ltd:企業の戦略的SWOT分析
    Intas Pharmaceuticals Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • US Foods Holding Corp (USFD):企業の財務・戦略的SWOT分析
    US Foods Holding Corp (USFD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Sysmex Corp (6869):製薬・医療:M&Aディール及び事業提携情報
    Summary Sysmex Corp (Sysmex) is a supplier of medical devices. It researches, develops, manufactures and sells instruments, reagents, and software applications that facilitate health checkups, treatment and disease management. The company offers diagnostic instruments, reagents and laboratory inform …
  • Renishaw Plc (RSW):企業の財務・戦略的SWOT分析
    Summary Renishaw Plc (Renishaw) is a medical device company that designs, manufactures and markets measurement, motion control, spectroscopy and precision machining products. The company offers precision measurement and process control, position and motion control, 3D laser scanning and measurement, …
  • Majesco
    Majesco - Strategy, SWOT and Corporate Finance Report Summary Majesco - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • EVN AG (EVN):企業の財務・戦略的SWOT分析
    EVN AG (EVN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • CSS Industries, Inc. (CSS):企業の財務・戦略的SWOT分析
    CSS Industries, Inc. (CSS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • British American Tobacco Bangladesh:企業の戦略・SWOT・財務情報
    British American Tobacco Bangladesh - Strategy, SWOT and Corporate Finance Report Summary British American Tobacco Bangladesh - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • SAS AB:戦略・SWOT・企業財務分析
    SAS AB - Strategy, SWOT and Corporate Finance Report Summary SAS AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Filtronic plc:企業の戦略・SWOT・財務分析
    Filtronic plc - Strategy, SWOT and Corporate Finance Report Summary Filtronic plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Microbot Medical Inc (MBOT):製薬・医療:M&Aディール及び事業提携情報
    Summary Microbot Medical Inc (Microbot), formerly StemCells Inc, a subsidiary of Stem Cell Sciences UK Ltd, is a medical device company that develops pharmaceutical, cell based therapeutics and related tools. The company provides research on products for spinal cord injury, thoracic injury, cervical …
  • Proximus plc:企業の戦略・SWOT・財務分析
    Proximus plc - Strategy, SWOT and Corporate Finance Report Summary Proximus plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • University of Alberta-製薬・医療分野:企業M&A・提携分析
    Summary University of Alberta (UALBERTA) is an educational university that provides undergraduate, international, graduate, continuing studies and open studies programs. The university offers educational programs in agricultural food and nutritional science, English and film studies, history and cla …
  • Sul America SA:企業の戦略・SWOT・財務情報
    Sul America SA - Strategy, SWOT and Corporate Finance Report Summary Sul America SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Andritz AG (ANDR):企業の財務・戦略的SWOT分析
    Andritz AG (ANDR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Euromoney Institutional Investor PLC:企業の戦略・SWOT・財務分析
    Euromoney Institutional Investor PLC - Strategy, SWOT and Corporate Finance Report Summary Euromoney Institutional Investor PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Sutro Biopharma Inc (STRO):製薬・医療:M&Aディール及び事業提携情報
    Summary Sutro Biopharma Inc (Sutro Biopharma), formerly Fundamental Applied Biology Inc, discovers, develops and manufactures novel cancer medicines which include antibody-drug conjugates (ADC’s), bispecific antibodies, and antibody-based therapeutics targeting immuno-oncology pathways. Its pipeline …
  • Gammon Infrastructure Projects Ltd (GAMMNINFRA)-エネルギー分野:企業M&A・提携分析
    Summary Gammon Infrastructure Projects Limited (GIPL) is an infrastructure project development company. It undertakes projects on a public private partnership basis (PPP) across various sectors including hydro power, roads and expressways, ports, urban infrastructure, airports, special economic zone …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆